103
Reference
1. Zubay, G. L., Biochemistry; 4Ed, Worthington, R., Ed.:McGraw-Hill
Companies, Inc.: Dubuque, 1998.
2. Dugas, H., Bioorganic Chemistry; Cantor, C. R., Ed.; Springer: New York,
1996.
3. Gaál, J.; Hermecz, I., Inhibitors of Monoamine Oxidase B: Pharmaclogy
and Clinical Use in Neurodegenerative Disorders; Szelenyi, I., Ed.: Birkhauser:
Boston; Berlin, 1993.
4. Silverman, R. B., Mechanism-based enzyme inactivators. Methods in
Enzymol. 1995, 249, 240.
5. Silverman, R. B., Radical Ideas about Monoamine Oxidase. Acc Chem Res
1995, 28, 335.
6. Shaoyong Ke; Zhong Li; Xuhong Qian., 1,3,4-Oxadiazole-3(2H)-
carboxamide derivatives as potential novel class of monoamine oxidase (MAO)
inhibitors: Synthesis, evaluation, and role of urea moiety. Bioorg Med Chem
2008, 16, 7565-7572.
104
7. Kalgutkar, A. S.; Dalvie, D. K.; Castagnoli, N., Jr.; Taylor, T., Chem Res
Toxicol 2001, 14, 1139-1162.
8. Haung, R. H.; Faulkner, R. The role of phospholipid in the multiple
functional forms of brain monoamine oxidase. J Biol Chem 1981, 256, 9211-
9215.
9. Cohen, G.; Farooqui, R.; Kesler, N., Parkinson disease: A new link
between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad
Sci U.S.A. 1997, 94, 4890-4894.
10. Edmondson, D. E.; Mattevi, A.; Binda, C.; Li, M.; Hubálek, F., Structure
and Mechanism of Monoamine Oxidase. Curr Med Chem 2004, 11, 1983-1993.
11. Youdim, M. B. H.; Finberg, J. P. M., New directions in monoamine
oxidase A and B selective inhibitors and substrates. Biochem Pharmacol 1991,
41, 155-162.
12. Gottowik, J.; Cesura, A. M.; Malherbe, P.; Lang, G.; Prada, M. D.,
Characterisation of wild-type and mutant forms of human monoamine oxidase
A and B expressed in a mammalian cell line. FEBS Lett 1993, 317, 152-156.
105
13. Geha, R. M.; Rebrin, I.; Chen, K.; Shih, J. C., Substrate and inhibitor
specificities for human monoamine oxidase A and B are influenced by a single
amino acid. J Biol Chem 2001, 276, 9877-9882.
14. Westlund, K. N.; Denney, R. M.; Kochersperger, L. M.; Rose, R. M.; Abell,
C. W., Distinct monoamine oxidase A and B populations in primate brain.
Science 1985, 230, 181-183.
15. Bach, A. W. J.; Lan, N. C.; Johnson, D. L.; Abell, C. W.; Bembenek, M.
E.; Kwan, S.W.; Seeburg, P. H.; Shih, J. C., cDNA cloning of human liver
monoamine oxidase A and B: molecular basis of differences in enzymatic
properties. Proc Natl Acad Sci U.S.A. 1988, 85, 4934-4938.
16. Grimsby, J.; Chen, K.; Wang, L. J.; Lan, N. C.; Shin, J. C., Human
monoamine oxidase A and B genes exhibit identical exon-intron organization.
Proc Natl Acad Sci U.S.A. 1991, 88, 3637-3641.
17. Binda, C.; Newton-Vinson, P.; Hubálek, F.; Edmondson, DE.; Mattevi, A.,
Structure of human monoamine oxidase B, a drug target for the treatment of
neurological disorders. Nat Struct Biol 2002, 9, 22-26.
106
18. Youdim, M.B.H.; Finberg, J.P.M.; Tipton, K.F., Monoamine oxidase. In:
Advances in Experimental Pharmacology. Catecholamine. II. ed. Trendelenburg,
U. & Weiner, U., Berlin: Springer-Verlag. 1988, 119-192.
19. Finberg, J.P.; Tenne, M., selective inhibition of monoamine oxidase types
A and B in the rat vas deferens. Br J Pharmacol 1982, 77, 13-21.
20. Finberg, J.P.; Tenne, M.; Youdim, M.B., Tyramine antagonistic properties
of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J
Pharmacol 1981, 73, 65-74.
21. Birkmayer, W.; Knoll, J.; Riederer, P.; Youdim, M.B.; Hars, V.; Marton,
J., Increased life expectancy resulting from addition of L-deprenyl to Madopar
treatment in Parkinson's disease: a longterm study. J Neural Transm 1985, 64,
113-127.
22. De Colibus, L.; Li, M.; Binda, C.; Lustig, A.; Edmondson, DE.; Mattevi,
A., Three-dimensional structure of human monoamine oxidase A (MAO A):
relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci
U.S.A 2005, 102, 12684-12689.
23. Binda, C.; Mattevi, A.; Edmondson, D E., Structure-function
relationships in flavoenzyme-dependent amine oxidations: a comparison of
107
polyamine oxidase and monoamine oxidase. J Biol Chem 2002, 277, 23973-
23976.
24. National Institute of Neurological disorders and Stroke NIH Institute,
Parkinson's Disease: Hope Through Research, 2008.
25. Magyar, K.; Pálfi, M.; Tábi, T.; Kalász, H.; Szende, B.; Szöko, E.,
Pharmacological aspects of (-)-deprenyl. Curr Med Chem 2004, 11, 2017-2031.
26. Baumgarten, H.G.; Zimmermann, G., In Handbook of Exp. Pharm.,
Springer-Verlag, 1992.
27. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I., Chronic Parkinsonism
in humans due to a product of meperidine-analog synthesis. Science 1983,
219, 979-980.
28. Crossman, A. R.; Clarke, C. E.; Boyce, S.; Robertson, R. G.; Sambrok, M.
A., MPTP-induced parkinsonism in the monkey: neurochemical pathology,
complications of treatment and pathophysiological mechanisms. Can J Neurol
Sci 1987, 14, 428-435.
29. Pifl, C.; Schingnitz, G.; Hornykievicz, O., The neurotoxin MPTP does not
reproduce in the rhesus monkey the interregional pattern of striatal dopamine
108
loss typical of human idiopathic Parkinson's disease. Neurosci Lett 1988, 92,
228-233.
30. Chiba, K.; Trevor, A.; Castagnoli, N. Jr., Metabolism of the neurotoxic
tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res
Commun 1984, 120, 574-578.
31. Dimonte, D. A.; Wu, E.Y.; Delanney, L. E.; Irwin, I.; Langston, J.W.,
Toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of
mouse astrocytes. J Pharmacol Exp Ther 1992, 261, 44-49.
32. Pifl, C.; Giros, B.; Caron, M. G., Dopamine transporter expression
confers cytotoxicity to low doses of the parkinsonism-inducing neurotoxin 1-
methyl-4-phenylpyridinium. J Neurosci 1993, 13, 4246-4253.
33. Peter, D.; Dimenez, J.; Liu, Y.; Kim, J.; Edwards, R. H., The chromaffin
granule and synaptic vesicle amine transporters differ in substrate recognition
and sensitivity to inhibitors. J Biol Chem 1994, 269, 7231-7237.
34. Lotharius, J.; O’Malley, K. L., The parkinsonism-inducing drug 1-methyl-
4-phenylpyridinium triggers intracellular dopamine oxidation. A novel
mechanism of toxicity. J Biol Chem 2000, 275, 38581-38588.
109
35. Nicklas,W. J.; Youngster, S. K.; Kindt, M. V.; Heikkila, R. E., MPTP,
MPP+ and mitochondrial function. Life Sci. 1987, 40, 721-729.
36. Nakamura, K.; Bindokas, V. P.; Marks, J. D.; Wright, D. A.; Frim, D. M.;
Miller, R. J.; Kang, U.J., The selective toxicity of 1-methyl-4-phenylpyridinium
to dopaminergic neurons: the role of mitochondrial complex I and reactive
oxygen species revisited. Mol Pharmacol 2000, 58, 271.
37. Waldmeier, P. C.; Boulton, A. A.; Cools, A. R.; Kato, A. C.; Tatton, W. G.,
Neurorescuing effects of the GAPDH ligand CGP 3466B. J Neural Transm Suppl.
2000, 60, 197-214.
38. Waldmeier, P. C.; Spooren, W. P.; Hengerer, B., CGP 3466 protects
dopaminergic neurons in lesion models of Parkinson's disease. Naunyn
Schmiedebergs Arch Pharmacol 2000, 362, 526-537.
39. Zimmermann, K.; Waldmeier, P.C., Tatton, W. G., Dibenzoxepines as
treatments for neurodegenerative diseases. Pure Appl Chem 1999, 71, 2039-
2046.
40. Langston, J. W.; Langston, E. B.; Irwin, I., MPTP-induced parkinsonism
in human and non-human primates--clinical and experimental aspects. Acta
Neurol. Scand. Suppl. 1984, 100, 49-54.
110
41. Ross, S. B.; Renyi, A.L., On the long-lasting inhibitory effect of N-(2-
chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) on the active uptake of
noradrenaline. J Pharm Pharmacol 1976, 28, 458-459.
42. Finnegan, K. T.; Skratt, J. S.; Irwin, I.; DeLanney, L. E.; Langston, J. W.,
Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its
inhibition of MAO B. Eur J Pharmacol 1990, 184, 119-126.
43. Ebadi, M.; Sharma, S.; Shavali, S.; El Refaey, H. J., Neuroprotective
actions of selegiline. Neurosci Res 2002, 67, 285-289.
44. Ricci, A.; Mancini, M.; Strocchi, P.; Bongrani, S.; Bronzetti, E., Deficits in
cholinergic neurotransmission markers induced by ethylcholine mustard
aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the
monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp Clin Res 1992, 18, 163-
171.
45. Youdim, M.B.; Bakhle, Y.S., Monoamine oxidase: isoforms and inhibitors
in Parkinson's disease and depressive illness. Br J Pharmacol 2006, 147, S287-
S296.
111
46. Yong, N.H.; Shi, Y. R.; Byung, H. H., Antioxidant Activity Resveratrol
Closely Correlates with Its Monoamine oxidase-A Inhibitory Activity. Arch
Pharm Res 1990, 13, 132-135.
47. Osman, F. Guner.; Douglas, R. Henry. Metric for Analyzing Hit Lists and
Pharmacophores. In Phamacophore Perception, Development, and Use in Drug
Design, Osman F. Guner., Ed.; International University Line: La Jolla,
California, 2000; pp 193-210.
48. Catalyst 4.11 User Guide, Accelrys Inc., San Diego, CA 92121, USA,
2005.
49. Debnath, A. K. Pharmacophore mapping of a series of 2,4-diamino-5-
deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate
reductase. J. Med. Chem. 2002, 45, 41-53.
50. Kurogi, Y.; Güner, O. F. Pharmacophore modeling and three-
dimensionaldatabase searching for drug design using catalyst. Curr. Med.
Chem. 2001, 8,1035–1055.
51. Johnston, JP., Some observations upon a new inhibitor of
monoamineoxidase in brain tissue. Biochem Pharmacol 1968, 17, 1285–1297.
112
52. Shih, JC.; Chen, K.; Ridd, MJ., Monoamine oxidase: from genes
tobehavior. Annu Rev Neurosci 1999, 22, 197-217.
53. Fowler, JS.; Logan, J.; Wang, G.J.; Volkow, N.D.; Telang, F.; Zhu, W.;
Franceschi, D.; Pappas, N.; Ferrieri, R.; Shea, C.;, Garza, V.; Xu, Y.; Schlyer,
D.; Gatley, S.J.; Ding, Y.S.; Alexoff, D.; Warner, D.; Netusil, N.; Carter, P.;
Jayne, M.; King, P.; Vaska, P., Low monoamine oxidase B in peripheral organs
in smokers. Proc Natl Acad Sci U S A. 2003, 100 (20), 11600-11605.
54. Kumar, M.J.; Nicholls, D.G.; Andersen, J.K., Oxidative alpha-
ketoglutarate dehydrogenase inhibition via subtle elevations in monoamine
oxidase B levels results in loss of spare respiratory capacity: implications for
Parkinson's disease. J Biol Chem 2003, 278 (47), 46432-46439.
55. Trendelenburg, U.; Weiner, N., Monoamine Oxidase, in: M.B.H. Youdim,
J.P.M. Finberg, K.F. Tipton (Eds.), Advances in Experimental Pharmacology,
Springer-Verlag, Berlin, 1988, 119–192.
56. Knoll, J.; Magyar, K., Some puzzling pharmacological effects of
monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972, 5, 393-
408.
113
57. Bohm, H.J.; Flohr, A.; Stahl, M., Scaffold hopping, Drug Discov Today
Technol, 2004, 1, 217–224.
58. Zhao, H., Scaffold selection and scaffold hopping in lead generation: a
medicinal chemistry perspective. Drug Discov Today, 2007, 12, 149–155.
59. Ertl, P.;, Jelfs, S.; Mühlbacher, J.; Schuffenhauer, A.; Selzer, P., Quest
for the rings. In silico exploration of ring universe to identify novel bioactive
heteroaromatic scaffolds, J Med Chem, 2006, 49, 4568-4573.
60. Gritsch, S.; Guccione, S.; Hoffmann, R.; Cambria, A.; Raciti, G.; Langer,
T., 3D QSAR study of monoamino oxidase-B inhibitors using the chemical
function based pharmacophore generation approach, J Enzyme Inhib, 2001,
16, 199–215.
61. Maestro, Version 1.0.9113, Schrodinger, L.L.C., New York, 2006.
62. Glide, Version 3.5, Schrodinger, L.L.C., New York, 2006.
63. Cerius2, Version 4.11, Accelrys Inc., San Diego, CA 92121, USA, 2007.
64. Catalyst, Version 4.11, Accelrys Inc., San Diego, CA 92121, USA, 2007.
114
65. Nesrin, G.; Akgul, Y.S.; Gulberk, U.; Kevser, E.; Altan, A.B., 1-N-
Substituted Thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and
Evaluation as MAO Inhibitors, Arch Pharm Pharm Med Chem, 2003, 336, 362–
371.
66. Herraiz, T.; Chaparro, C., Human monoamine oxidase is inhibited by
tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors.
Biochem Biophys Res Commun, 2005, 326, 378–386.
67. Yáñez, M.; Fraiz, N.; Cano, E.; Orallo, F., Inhibitory effects of cis- and
trans-resveratrol on noradrenaline and 5-hydroxytryptamine uptake and on
monoamine oxidase activity, Biochem Biophys Res Commun, 2006, 344, 688–
695.
68. Tao, G.; Irie, Y.; Li, D.J.; Keung, W.M., Eugenol and its structural
analogs inhibit monoamine oxidase A and exhibit antidepressant-like activity,
Bioorg Med Chem, 2005, 13, 4777–4788.
69. Chimenti, F.; Bolasco, A.; Manna, F.; Secci, D.; Chimenti, P.; Granese,
A.; Befani, O.; Turini, P.; Alcaro, S.; Ortuso, F., Synthesis and molecular
modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent
and highly selective monoamine oxidase-A inhibitors, Chem Biol Drug Des,
2006, 67, 206–214.
115
70. Hutchinson, D.K., Oxazolidinone antibacterial agents: a critical review,
Curr Top Med Chem, 2003, 3, 1021–1042.
71. Rosen, T.C.; Yoshida, S.; Fröhlich, R.; Kirk, K.L.; Haufe, G., Fluorinated
phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of
absolute configuration on inhibition of microbial tyramine oxidase, J Med
Chem, 2004, 47, 5860–5871.
72. Hubálek, F.; Binda, C.; Li, M.; Herzig, Y.; Sterling, J.; Youdim, M.B.;
Mattevi, A.; Edmondson, DE., Inactivation of purified human recombinant
monoamine oxidases A and B by rasagiline and its analogues, J Med Chem,
2004, 47, 1760–1766.
73. Wang, E.Y.; Gao, H.; Salter, C.L.; Zhang, J.; Huang, L.; Podar, E.M.;
Miller, A.; Zhao, J.; O'rourke, A.; Linnik, M.D., J Med Chem, 2006, 49, 2166–
2173.
74. Debnath, A.K., Pharmacophore mapping of a series of 2,4-diamino-5-
deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate
reductase, J Med Chem, 2002, 45, 41–53.
116
75. Vadivelan, S.; Sinha, B.N.; Irudayam, S.J.; Jagarlapudi, S.A., Virtual
screening studies to design potent CDK2-cyclin A inhibitors, J Chem Inf Model,
2007, 47, 1526–1535.
76. Vadivelan, S.; Sinha, B.N.; Rambabu, G.; Boppana, K.; Jagarlapudi, S.A.,
Pharmacophore modeling and virtual screening studies to design some
potential histone deacetylase inhibitors as new leads, J Mol Graph Model, 2008,
26, 935–946.
77. Vadivelan, S.; Sinha, B.N.; Sunita, T.; Sarma, J.A.R.P., Fragment and
knowledge-based design of selective GSK-3ß inhibitors using virtual screening
models, Eur J Med Chem, 2009, 44, 2361-2371.
78. Guner, O.F.; Henry, D.R.; Phamacophore Perception, Development, and
Use in Drug Design, Osman F. Guner (Ed.), International University Line, La
Jolla, California, 2000, 193–210.
79. Berman, H. M.; Bhat, T. N.; Bourne, P. E.; Feng, Z.; Gilliland, G.;
Weissig, H.; Westbrook, J. The Protein Data Bank and the challenge of
structural genomics. Nature Struct. Biol. 2000, 7, 957–959.
80. Westbrook, J.; Feng, Z.; Chen, L.; Yang, H.; Berman, H. M. The Protein
Data Bank and structural genomics. Nucleic Acid Res. 2003, 31, 489–491.
117
81 Blundell, TL.; Jhoti, H.; Abell, C. High-throughput crystallography for
lead discovery in drug design. Nature Rev. Drug Discov. 2002, 1, 45–54.
82 Chen, H.; Lyne, P. D.; Giordanetto, F.; Lovell, T.; Li, J. On evaluating
molecular-docking methods for pose prediction and enrichment factors. J.
Chem. Inf. Model. 2006, 46, 401-415.
83. Bissantz, C.; Folkers, G.; Rognan, D. Protein-based virtual screening of
chemical databases. 1. Evaluation of different docking/scoring combinations.
J. Med. Chem. 2000, 43, 4759-4767.
84. Glen, R. C.; Allen, S. C. Ligand-protein docking: cancer research at the
interface between biology and chemistry. Curr. Med. Chem. 2003, 10, 763-777.
85. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and
scoring in virtual screening for drug discovery: methods and applications. Nat.
Rev. Drug Discovery, 2004, 3, 935-949.
86. Ingo, Muegge.; Istvan, J. Enyedy. Virtual Screening of Kinase Targets.
Curr. Med. Chem. 2004, 11, 693-707.
118
87. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.;
Weissig, H.; Shindyalov I. N.; Bourne P. E. The Protein Data Bank. Nucleic
Acids Res. 2000, 28, 235-242.
88. Gohlke, H.; Klebe, G. Statistical potentials and scoring functions applied
to protein-ligand binding. Curr. Opin. Struct. Biol. 2001, 11, 231–235.
89. Marcel, L. Verdonk.; Jason, C. Cole.; Michael, J. Hartshorn.;
Christopher, W. Murray.; Richard, D. Taylor. Improved protein-ligand docking
using GOLD. Proteins: Structure, Function, and Genetics 2003, 52, 609–623.
90. Bartosz, A. Grzybowski.; Alexey, V. Ishchenko.; Chu-Young Kim.; George
Topalov.; Robert Chapman.; David, W. Christianson.; George, M. Whitesides.;
Eugene, I. Shakhnovich. Combinatorial computational method gives new
picomolar ligands for a known enzyme. J. Comput.-Aided Mol. Des., 1997, 11,
425-445.
91. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead D. R.; Eldridge, M.
D. Flexible Docking Using Tabu Search and an Empirical Estimate of Binding
Affinity. Proteins, 1998, 33, 367-382.
92. Glide, version 3.5; Schrodinger, L.L.C., New York, 2006.
119
93. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.;
Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D.
E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate
docking and scoring. 1. Method and assessment of docking accuracy. J. Med.
Chem. 2004, 47, 1739-1749.
94. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.;
Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking
and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004,
47, 1750-1759.
95. Cerius2 4.11 User Guide, Accelrys Inc., San Diego, CA 92121, USA,
2005.
96. Hodgson, J., ADMET--turning chemicals into drugs. Nat Biotechnol
2001, 19, (8), 722-6
97. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.;
Edmondson, D.E.; Mattevi, A., Structures of human monoamine oxidase B
complexes with selective noncovalent inhibitors: safinamide and coumarin
analogs, J Med Chem, 2007, 50, 5848–5852.
120
98. Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig,
H.; Shindyalov, I.N.; Bourne, P.E., The Protein Data Bank, Nucleic Acids Res,
2000, 28, 235–242.
99. Barros, A. I. R. N. A.; Silva, A. M. S.; Alkorta, I.; Elguero, J. Synthesis,
experimental and theoretical NMR study of 2’-hydroxychalcones bearing a nitro
substituent on their B ring, Tetrahedron, 2004, 60, 6513-6521.
100. Sharma, T. C.; Saksena, V.; Reddy, N. J., Oxidation of some
hydroxyarylpyrazolines with manganese dioxide, Acta Chim. Acad. Sci. Hungar.,
1977, 93, 415-419.
101. Gokhan, N.; Yesilada, A.; Ucar, G.; Erol, K.; Bilgin, A. A., 1-N-Substituted
Thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: Synthesis and Evaluation as
MAO Inhibitors, Arch. Pharm. (Weinheim, Ger.) 2003, 336, 362-371.
102. Holt, A.; Sharman, D. F.; Baker, G. B.; Palcic, M. M., A continuous
spectrophotometric assay for Monoamine Oxidase and related enzymes in
tissue homogenates, Anal. Biochem. 1997, 244, 384-392.
103. Bradford, M. M. A, rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of Protein-Dye Binding,
Anal. Biochem. 1976, 72, 248-254.